Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Yeast-Based Virus-like Particles as an Emerging Platform for Vaccine Development and Delivery

18 Feb 2023

Abstract excerpt

Virus-like particles (VLPs) are empty, nanoscale structures morphologically resembling viruses. Internal cavity, noninfectious, and particulate nature with a high density of repeating epitopes, make them an ideal platform for vaccine development and drug delivery. Commercial use of Gardasil-9 and Cervarix showed the usefulness of VLPs in vaccine formulation. Further, chimeric VLPs allow the raising of an immune...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Bacteriophages and microbial interactions
Share to Viral gastroenteritis research and epidemiology
Share to Virus-based gene therapy research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 36851356
DOI: 10.3390/vaccines11020479

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Yeast-Based Virus-like Particles as an Emerging Platform for Vaccine Development and DeliveryPMID 36851356Read ↗

Advances and challenges in enveloped virus-like particle (VLP)-based vaccinesSemantic proximity Read ↗

Platforms, advances, and technical challenges in virus-like particles-based vaccinesSemantic proximity Read ↗

Virus-like particles: flexible platforms for vaccine developmentSemantic proximity Read ↗

From concept to delivery: a yeast-expressed recombinant protein-based COVID-19 vaccine technology suitable for global accessSemantic proximity Read ↗

Production of virus-like particles for vaccinesSemantic proximity Read ↗

Virus‐like particles as powerful vaccination strategy against human virusesSemantic proximity Read ↗

Vaccination, immune and gene therapy based on virus-like particles against viral infections and cancerSemantic proximity Read ↗

Virus-like particles as a highly efficient vaccine platform: Diversity of targets and production systems and advances in clinical developmentSemantic proximity Read ↗

Comparative Molecular Biology Approaches for the Production of Poliovirus Virus-Like Particles Using Pichia pastorisSemantic proximity Read ↗

Virus-like particles: preparation, immunogenicity and their roles as nanovaccines and drug nanocarriersSemantic proximity Read ↗

Expression and Characterization of Yeast Derived Chikungunya Virus Like Particles (CHIK-VLPs) and Its Evaluation as a Potential Vaccine CandidateSemantic proximity Read ↗

Prokaryote- and Eukaryote-Based Expression Systems: Advances in Post-Pandemic Viral Antigen Production for VaccinesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.